RxDoctor Payments Data

Jack Kleid, MD

Cardiovascular Disease · San Diego, CANPI 1033381124

Payments from drug & device makers

$5,316in general payments, 2019–2025

Across 216 payments — averaging $24.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Novartis$746
  • Pfizer$677
  • Novo Nordisk$393
  • Amarin Pharma, Inc.$342
  • Merck$293
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$5,292100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,316 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$163,528
Medicare patients
99
Services billed
1,564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$30,719
JardianceEmpagliflozin16$19,562
XareltoRivaroxaban20$19,534
EdarbyclorAzilsartan Med/Chlorthalidone23$16,829
Repatha SureclickEvolocumab19$13,319
VascepaIcosapent Ethyl18$9,903
Icosapent Ethyl15$5,936
Losartan Potassium117$1,468
Amlodipine Besylate135$1,196
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med16$972
Levothyroxine Sodium37$694
Nebivolol Hcl18$679
Atorvastatin Calcium62$674
Rosuvastatin Calcium47$663
ClopidogrelClopidogrel Bisulfate18$560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$677$30,71943 claims
Boehringer IngelheimJardiance$114$19,56216 claims
Johnson & JohnsonXarelto$90$19,53420 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$75$16,82923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →